MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-14-2024
Acutus Medical Cost of Revenue 2011-2026 | AFIB
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Acutus Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.3 M | 4.94 M | 32.9 M | 15.9 M | 9.24 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 32.9 M | 4.94 M | 14.7 M |
Quarterly Cost of Revenue Acutus Medical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.89 M | 4.47 M | 3.66 M | - | 3.15 M | 2.53 M | 2.11 M | - | 6.95 M | 9.7 M | 6.94 M | - | 8.54 M | 7.49 M | 6.96 M | - | 5.14 M | 2.66 M | 3.19 M | - | 2.27 M | 2.44 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.7 M | 2.11 M | 4.89 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Medtronic PLC
MDT
|
11.6 B | $ 87.12 | 0.62 % | $ 112 B |  USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.13 | 6.22 % | $ 1.29 M | USA |
 |
Orthofix Medical
OFIX
|
256 M | $ 11.97 | 2.13 % | $ 474 M |  Curacao |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Inogen
INGN
|
194 M | $ 6.3 | -0.4 % | $ 168 M | USA |
 |
IRadimed Corporation
IRMD
|
19.5 M | $ 102.82 | 1.83 % | $ 1.31 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
LENSAR
LNSR
|
27.6 M | $ 5.66 | 1.8 % | $ 65.2 M | USA |
 |
Insulet Corporation
PODD
|
768 M | $ 225.87 | 0.16 % | $ 15.9 B | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 33.16 | 1.69 % | $ 1.53 B | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 36.85 | 0.72 % | $ 1.14 B | USA |
 |
AVITA Medical
RCEL
|
12.8 M | $ 4.04 | 5.21 % | $ 113 M |  Australia |
 |
NanoVibronix
NAOV
|
1.05 M | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
14 M | $ 24.7 | 0.2 % | $ 209 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.65 | -7.27 % | $ 35.4 M | USA |
 |
Aethlon Medical
AEMD
|
3.87 M | $ 2.25 | 3.94 % | $ 3.51 M | USA |
 |
InspireMD
NSPR
|
6.33 M | $ 1.79 | 1.13 % | $ 115 M |  Israel |
 |
Profound Medical Corp.
PROF
|
3.92 M | $ 5.23 | 1.55 % | $ 180 M | Canada |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Sintx Technologies
SINT
|
557 K | $ 2.62 | 1.95 % | $ 7.27 M | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 11.61 | 1.13 % | $ 1.57 B | USA |
 |
Myomo
MYO
|
14 M | $ 0.72 | 3.24 % | $ 30.1 M | USA |
 |
Smith & Nephew plc
SNN
|
1.54 B | $ 32.46 | 0.92 % | $ 23.8 B |  Britain |
 |
Penumbra
PEN
|
461 M | $ 335.79 | 0.46 % | $ 13.1 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
21.9 M | $ 2.4 | - | $ 141 M | Israel |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.69 | -5.63 % | $ 138 M |  France |
 |
Sensus Healthcare
SRTS
|
15.6 M | $ 3.96 | - | $ 64.7 M | USA |
 |
Quanterix Corporation
QTRX
|
73.9 M | $ 3.95 | 3.4 % | $ 168 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 16.04 | 0.82 % | $ 376 M | USA |
 |
Outset Medical
OM
|
72.7 M | $ 3.56 | 0.85 % | $ 54.2 K | USA |